Figure 1.

Generation and Characterization of iPSCs from FTD MAPT R406W Patients

(A and B) Immunofluorescence for pluripotency markers alkaline phosphatase (A) and TRA-1-60 (B). Representative clones from each patient are shown. Scale bars, 500 μm.

(C) Schematic diagram of the construction of targeting vectors. Top: construct of the WT targeting vector for the generation of WT lines. Bottom: construct of the mutant targeting vector for the generation of homozygous mutant lines.

(D) DNA sequence of the mutation site in the heterozygous patient line (MAPT^R406W/+) and in the gene-edited isogenic lines (WT line: MAPT^+/+, homozygous mutant line: MAPT^R406W/R406W).

See also Figure S1.